⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881388 | 0.84 | — | — | |
| SCHEMBL12393317 | 0.84 | — | — | |
| SCHEMBL18214612 | 0.82 | — | — | |
| SCHEMBL12261239 | 0.82 | — | — | |
| SCHEMBL16502855 | 0.82 | CA12 (0.39) | — | |
| SCHEMBL12253912 | 0.82 | CA12 (0.39) | — | |
| SCHEMBL14010624 | 0.80 | — | — | |
| SCHEMBL10148561 | 0.80 | — | — | |
| SCHEMBL14143383 | 0.79 | PRMT5 (0.41) | — | |
| SCHEMBL16330651 | 0.79 | PRMT5 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280973-B1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8012941-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012941-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009132123-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |